Trial of UFT for Advanced Colorectal and Gastric Cancer
Author Information
Author(s): S.T.A. Malik, D. Talbot, P.I. Clarke, R. Osborne, R. Reznekl, P.F.M. Wrigley, M.L. Slevin
Primary Institution: ICRF Department of Medical Oncology, St Bartholomew's and Homerton Hospitals, London, UK
Hypothesis
Does oral UFT provide effective treatment for advanced colorectal and gastric cancer?
Conclusion
Oral UFT shows some efficacy in treating metastatic colorectal cancer but has a low response rate in gastric cancer.
Supporting Evidence
- Six partial responses were seen in colorectal cancer patients, indicating a response rate of 16.6%.
- One partial response was observed in gastric cancer patients, with a response rate of 6%.
- The overall toxicity of UFT was low, allowing outpatient treatment.
Takeaway
This study tested a new cancer treatment called UFT on patients with advanced colorectal and stomach cancer, finding it works better for colon cancer.
Methodology
Patients received continuous oral therapy with UFT for at least three months, with evaluations every two weeks initially.
Limitations
The study had a small sample size and a low response rate in gastric cancer.
Participant Demographics
{"colorectal_cancer":{"total_patients":40,"evaluable":36,"male":27,"female":13,"mean_age":59},"gastric_cancer":{"total_patients":18,"evaluable":16,"male":14,"female":4,"mean_age":63}}
Statistical Information
Confidence Interval
{"colorectal_cancer":"95% confidence limits 6.4-32.8%","gastric_cancer":"95% confidence limits 0.27-30.2%"}
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website